

3 OPEN ACCESS

The COBATEST network: a platform to perform monitoring and evaluation of HIV community-based testing practices in Europe and conduct operational research

L. Fernàndez-López^{a,b} , J. Reyes-Urueña^a , C. Agustí^{a,b}, T. Kustec^c, I. Klavs^c, C. Casabona^{a,b} and the COBATEST Network group

^aCentre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Badalona, Spain; ^bCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; ^cNational Institute of Public Health, Ljubljana, Slovenia

ABSTRACT

The European project "HIV community-based testing practices in Europe" (HIV-COBATEST) has contributed to the establishment of a network of community-based voluntary counselling and testing services (CBVCTs) that monitors and evaluates HIV testing activity in the communities. The objective of this paper is to describe the data that have been collected during 2014 by the COBATEST network in order to provide an insight into testing activity of CBVCTs in Europe. Members of the CBVCT network share common instruments for data collection and data entry. The network has a common database that allows global data analysis and comparison between different centres. In 2014, 40 CBVCTs of 18 European countries were participating in the network, and, from those, 20 CBVCTs were using the common COBATEST data collection tools. In these 20 CBVCTs, a total of 9266 HIV screening tests were performed on 8554 people, of which 1.58% (135/8554) were reactive and 51.1% (69/135) confirmed positive. Five cases were false positives, and 84.1% (58/69) of the confirmed positive cases were linked to care. Most of the tested individuals were men (70.8%), between 21 and 35 years of age (57.6%) and natives (67.1%). A higher proportion of men who had sex with men (MSM) (38.8%; 3267/8554) were tested compared to heterosexual men (27.7%) and women (23.5%). Rapid blood test was used in 78.5% of the cases and mostly performed in CBVCT offices (88.3%). Among sex workers (SWs), the percentage of reactive screening tests was particularly high (4.0%), especially among male SWs (7.7%) as compared to other risk groups, such as MSM (3.1%). The COBATEST network contributes to the availability of standardized information about the activity and impact of CBVCT centres in Europe. This information and standardized tools can help improve these services and inform decision-makers to better contextualize these interventions within their national HIV-prevention programmes.

ARTICLE HISTORY

Received 2 October 2015 Accepted 20 January 2016

KEYWORDS

HIV infection–diagnosis– prevention and control– therapy; early diagnosis; counselling; community health services; health services accessibility; Europe

Background

HIV infection remains of major public health importance in Europe. A total of 136,235 new HIV diagnoses of infections were reported in 51 countries in 2013, a rate of 15.7 per 100,000 population (European Centre for Disease Prevention and Control, 2014) and approximately 900,000 people are living with HIV in Western and Central Europe (UNAIDS, 2013). However, the exact number of people infected remains unknown. In Europe, recent estimates of the proportion of infected individuals who are undiagnosed ranged from 20% to 40% (Birrell et al., 2013; Hamers & Phillips, 2008; van Sighem et al., 2015).

Evidence suggests that a reduction in the proportion of people with undiagnosed HIV infection will be achieved through expansion in the coverage and frequency of HIV testing (European Centre for Disease Prevention and Control, 2011). Therefore, with the aim of improving targeted testing for people most likely to be infected with HIV, European policies are increasingly promoting community-based voluntary counselling and testing services (CBVCTs) (European Commission, 2009; Jakab & Marmot, 2012; World Health Organization, 2010). These centres are recognized to be a good model for improving access to testing for HIV services for key populations (Suthar et al., 2013).

The European project HIV community-based testing practices in Europe (HIV-COBATEST) was implemented from 2010 to 2012, in order to promote early diagnosis of HIV infection in Europe by improving CBVCT practices. This project has contributed to the establishment of a network of CBVCT services (COBATEST network) and

CONTACT L. Fernàndez-López 🔯 Iflopez@iconcologia.net 🔁 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Spain

has developed standard data collection instruments and procedures to promote HIV testing and counselling for hard-to-reach key populations.

A survey performed as part of the HIV-COBATEST project showed that HIV/AIDS National Focal Points did not have reliable information on CBVCTs in their countries (Reyes-Urueña et al., 2015), demonstrating a need to collect data at CBVCTs and make it available and useful for National HIV Programmes. The objective of this paper is to describe the data that have been collected during 2014 by the COBATEST network, from individual CBVCTs using the common tools, in order to provide an insight into CBVCTs testing activity in Europe.

Methods

We undertook a descriptive study analysing HIV testing activity of CBVCTs in the COBATEST network. All data for 2014 were collected from individual centres using common data collection and web-based data entry tools. Information was collected on paper during the client's visit for HIV testing at the CBVCTs and subsequently entered on the web-based data entry tool.

The standardized questionnaire included questions related to socio-demographic characteristics, risk behaviours and HIV testing results. Data were entered into a centralized database that allowed global and stratified analysis of pooled data from all participating centres. CBVCTs use a unique Client Identification Code that ensured the anonymity of the client and allowed the identification of repeat testers. Each CBVCT centre had access to its own disaggregated data in the common data-set. The descriptive analysis included socio-demographic characteristics, risk behaviour and HIV testing results. Results for the percentage of people with a reactive screening test were stratified by sex, age group and key population. Data analysis was performed using PASW Statistics for Windows, version 18.0.

Results

In 2014, 20 of the 40 member CBVCTs from 18 European countries who form the network were using the common data collecting tools and were included in this analysis. A total of 9266 HIV screening tests were performed on 8554 individuals, of which 1.6% (135/8554) were reactive. Of these reactive tests, 63.1% (69/135) had a confirmatory test, 51.1% (69/135) of which were confirmed as positive, and 84.1% (58/69) of the confirmed positives were successfully linked to care (Figure 1). There were five people with reactive screening test results who were linked to care without having a confirmatory test through the CBVCTs.




Figure 1. Key performance indicators of the COBATEST CBVCT centres, collected through the COBATEST network's* tools during 2014. *Only data from CBVCTs that used the common data entry tool were included in the analyses.

There were five false positive results, all men. One was a person who injected drugs (PWID), two were men who had sex with men (MSM) and two were heterosexuals. In four of these cases, the test was performed on blood, the last on an oral sample.

Four individuals with confirmed HIV infection were not linked to care and for seven the information about linkage to care was missing. Of these 11 cases, 10 were MSM and one a female sex worker (SW). Three of the cases not linked to care were tourists.

Most of the tested individuals were men (70.8%) aged between 21 and 35 years (57.6%) and natives (67.1%). A higher proportion of persons tested were MSM (38.8%) in comparison to heterosexual men (27.7%) or women (23.5%). Rapid blood tests were used in 78.5% of cases and were mostly performed in CBVCT offices (88.3%) (Table 1). Among the total number of tested individuals, 35.7% were new testers.

Table 2 presents the percentage of reactive screening tests stratified by sex, age group and key population. The percentage of reactive screening tests was particularly high among SWs (4.0%), especially male SWs (7.7%), as compared to other risk groups, such as MSM (3.1%). It is noteworthy that no PWID had a reactive test result as not many CBVCTs participating in this network were serving PWID.

Discussion

Our results show that the people accessing the CBVCTs in the COBATEST network were mostly MSM, between 21

Table 1. Socio-demographic characteristics, risk behaviour and HIV testing information for people that have been tested during 2014 in the CBVCTs participating in the COBATEST networka.

	Ν	Percentage
Gender		
Male	6057	70.8
Female	2370	27.7
Transgender	125	1.5
Age groups		
<20	728	8.7
≥21–35	4795	57.6
>36-50	2238	26.9
>50	566	6.8
Migrants		
Yes	2811	32.9
Key populations		
PWID	134	1.6
Male sex worker	346	4.1
MSM	3267	38.8
Women sex worker	365	4.3
Heterosexual women	1983	23.5
Heterosexual men	2334	27.7
Type of test used		
Rapid blood test	6717	78.5
Rapid oral test	1679	19.6
Conventional test	156	1.8
Testing sites		
CBVCT office	7556	88.3
Outdoors/Van	23	0.30
Sex work venue	56	0.7
Sauna/sex venue	176	2.1
Public venue	48	0.6
Amusement venue	192	2.2
Other	503	5.9
Previous HIV test	300	5.5
Yes	5500	64.3
	-500	0.15

PWID, people who inject drugs; MSM, men who have sex with men; CBVCTs, community-based voluntary counselling and testing services.

and 35 years old, and native. Although the pooled prevalence estimate was not very high (1.6%), the prevalence estimates among specific groups, such as MSM (3.1%), and, especially, male SW (7.7%) were much higher, suggesting that these particular CBVCTs are mainly targeting MSM rather than other key populations. It is important to note that just 11.7% of tests were performed during outreach activities. Finally, since the percentage of people reported as first-time testers (35.7%) was high, our results showed the great potential of CBVCT services to reach people who have never been tested.

Although there was a high number of people with a reactive screening test who did not have a confirmatory test, subsequent checking in a subset of CBVCTs revealed discrepancies between data in the database (around 35% of individuals with a reactive test had no confirmatory test) and direct reports from those centres. Those reports stated that almost 99% of individuals with a reactive screening HIV test were confirmed, suggesting that information about confirmation could sometimes be not introduced because it is collected at a later stage.

Table 2. Percentage of reactive HIV screening tests stratified by sex, age group and key population among individuals tested during 2014 in the CBVCTs participating in the COBATEST networka.

network .					
All	All	Males	Females	<25	≥25
Numerator: Number of clients with reactive screening HIV test result	135	73	12	18	71
Denominator: Number of clients tested for HIV with a screening test	8554	6182	2370	2038	6289
Percentage of clients with reactive screening HIV test result MSM	1.58	1.93	1.09	1.51	2.0
Numerator: Number of clients with reactive screening HIV test result	111	111	-	27	82
Denominator: Number of clients tested for HIV with a screening test	3546	3546	-	735	2732
Percentage of clients with reactive screening HIV test result	3.13%	3.13%	-	3.67%	3.00%
Numerator: Number of clients with reactive screening HIV test result	29	27	2	9	20
Denominator: Number of clients tested for HIV with a screening test	721	351	369	141	570
Percentage of clients with reactive screening HIV test result PWID	4.02	7.69	0.54	6.38	3.51
Numerator: Number of clients with reactive screening HIV test result	0	0	0	0	0
Denominator: Number of clients tested for HIV with a screening test	134	113	21	17	114
Percentage of clients with reactive screening HIV test result	0.00	0.00	0.00	0.00	0.00
Numerator: Number of clients with reactive screening HIV test result	63	48	15	16	46
Denominator: Number of clients tested for HIV with a screening test	2811	1812	999	646	2165
Percentage of clients with reactive screening HIV test result	2.24	2.65	1.50	2.47	2.12

PWID, people who inject drugs; MSM, men who have sex with men; SW, sex

Note: Individuals may be members of more than one key population at a time, so the categories are not mutually exclusive.

Our results, together with other studies (Suthar et al., 2013; Thornton, Delpech, Kall, & Nardone, 2012), indicate that CBVCTs are successful in diagnosing previously undiagnosed HIV infections among key populations, and that these centres have a substantial proportion of first-time testers. This is explained by the fact that CBVCTs are serving key populations with many access barriers to HIV testing. On the other

^aOnly data from CBVCTs that used the common data entry tool were included in the analyses.

^aOnly data from CBVCTs that used the common data entry tool were included in the analyses.

hand, our results showed that the percentage of confirmed cases linked to care was high (84.1%) compared to other studies 80.1% (95% CI 74.8-85.4%) (Suthar et al., 2013), although data may be not comparable, because of differing definitions of linkage to care. In most studies, linkage to care is defined as a CD4 count taken within 3 months of initial test, but because CD4 results are not often available to CBVCTs, this definition should be different. The concept of linkage to care from the perspective of CBVCTs should therefore be defined as the percentage of people with a reactive screening tests that had contact with specialist HIV care. Additional effort is needed within the COBATEST network to accurately measure linkage to care.

The data collected through the COBATEST network can be a source of strategic HIV-related evidence for the need to strengthen community-based service delivery models as an integral part of strategic HIV interventions, as recently stated in the Consolidated Strategic Information Guidelines (World Health Organization, 2015). Also, taking into account that CBVCT approaches have been successful in reaching key populations early in the course of HIV infection (Suthar et al., 2013), these data might lead to a deeper understanding of the context of the epidemic, such as the vulnerability and the risks to which key populations are exposed and the options for actions to reduce the burden of HIV.

An important limitation is that this analysis was conducted in CBVCTs that participate in the COBATEST network and use common tools. Results are therefore not generalizable to all CBVCTs in Europe, and cannot be representative at the national or European level, because in some countries there are several participating CBVCTs, but in most countries there is a single centre participating in the network. In a second phase, data from the remaining member CBVCTs of the COBAT-EST network will be included in the analysis, increasing both the data volume and its representativeness.

In conclusion, the first monitoring and evaluation results from the COBATEST network prove the feasibility of collecting standardized data from CBVCTs in different countries across Europe, as well as demonstrating usefulness of such data. The COBATEST network and its data contributions over time will be crucial in considering which CBVCT indicators should be included in the Dublin Declaration monitoring process, to better assess the cascade of prevention, care and treatment services and to improve the effectiveness of CBVCTs across Europe.

Acknowledgements

We are grateful to all colleagues from the CBVCT centres participating in the COBATEST network for their collaboration in

the network (AIDS Fondet* (Denmark), Fondazione LILA Milano* (Italy), Demetra* (Lithuania), Algarabía (Spain)*, AVACOS*, PRAKSIS*, CAS Gibraltar*, OMSIDA* (Spain), StopSida* (Spain), Ambit Prevenció* (Spain), Gais Positius* (Spain), SAPS-Creu Roja* (Spain), Centre Jove d'Anticoncepció i Sexualitat* (CJAS) (Spain), Creu Roja Tarragona* (Spain), Actuavallès* (Spain), ACASC* (Spain), Associació Antisida de Lleida* (Spain), Assexora'Tgn* (Spain), ACCAS* (Spain), Baltic HIV Association* (Latvia), ACAS Girona* (Spain), Asociación SILOÉ* (Spain), Associació Lambda* (Spain), Centro Social Polivalente Mujer Gades* (Spain), IEMEKAIE* (Spain), Gay-alliance (Ukraina), Asociación Concordia* (Spain); Cruz Roja Córdoba (Spain); Asociación ADHARA (Spain); Proyecto Hombre (Spain); Concordia Marbella (Spain); AIDS-Hilfe NRW e.V (Germany).; ARAS-Asociata Romana Anti-SIDA (Romania); Checkpoint LX (Portugal); Association AIDES (France); Legebitra (Slovenia); Czech AIDS Help Societ (Chez Republic); Association "Prevent" (Serbia); Positive Voice (Greece); AIDS Hilfe Wien (Austria); CBVCT network Poland; LASS (UK), Le Kioske (France); Anonymous AIDS Association (Hungary); ISKORAK(Croatia)). CBVCTs marked with an asterisk are those which contributed with data for this analysis.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was co-founded by CHAFEA [grant agreement no. 20091211].

ORCID

L. Fernàndez-López http://orcid.org/0000-0002-6353-

J. Reyes-Urueña b http://orcid.org/0000-0002-3122-6518

References

Birrell, P. J., Gill, O. N., Delpech, V. C., Brown, A. E., Desai, S., Chadborn, T. R., ... De Angelis, D. (2013). HIV incidence in men who have sex with men in England and Wales 2001-10: A nationwide population study. The Lancet. Infectious Diseases, 13(4), 313-318. http://dx.doi.org/10.1016/S1473-3099(12)70341-9

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. (2011). HIV/AIDS surveillance in Europe 2010. Stockholm: Author.

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. (2014). HIV/AIDS surveillance in Europe 2013. Stockholm: Author.

European Commission. (2009). 2009/158/EC: Commission decision of 23 February 2009 on the adoption of the Work Plan for 2009 for the implementation of the second programme of Community action in the field of health (2008 to 2013), and on the selection, award and other



- criteria for financial contributions to the actions of this programme (Text with EEA relevance).
- Hamers, F. F., & Phillips, A. N. (2008). Diagnosed and undiagnosed HIV-infected populations in Europe. *HIV Medicine*, 9(2), 6–12. http://doi.org/10.1111/j.1468-1293.2008.00584.x
- Jakab, Z., & Marmot, M. (2012). Social determinants of health in Europe. *Lancet (London, England)*, 379(9811), 103–105. doi:10.1016/S0140-6736(11)61511-0
- Reyes-Urueña, J., Breveglieri, M., Furegato, M., Fernàndez-López, L., Agusti, C., & Casabona, J. (2015). Heterogeneity of community-based voluntary, counselling and testing services for HIV in Europe: The HIV-COBATEST survey. *International Journal of STD & AIDS*. http://doi.org/10.1177/0956462415623402
- van Sighem, A., Nakagawa, F., De Angelis, D., Quinten, C., Bezemer, D., de Coul, E. O., ... Phillips, A. (2015). Estimating HIV incidence, time to diagnosis, and the undiagnosed HIV epidemic using routine surveillance data. *Epidemiology (Cambridge, Mass.)*, 26(5), 653–660.

- Suthar, A. B., Ford, N., Bachanas, P. J., Wong, V. J., Rajan, J. S., Saltzman, A. K., ... Baggaley, R. C. (2013). Towards universal voluntary HIV testing and counselling: A systematic review and meta-analysis of community-based approaches. *PLoS Medicine*, 10(8), e1001496. http://doi.org/10.1371/journal.pmed.1001496
- Thornton, A. C., Delpech, V., Kall, M. M., & Nardone, A. (2012). HIV testing in community settings in resource-rich countries: A systematic review of the evidence. *HIV Medicine*, *13*(7), 416–426. http://doi.org/10.1111/j.1468-1293.2012.00992.x
- UNAIDS. (2013). Global report. UNAIDS report on the global AIDS epidemic 2013. Geneva: Author.
- World Health Organization. (2010). Scaling up HIV testing and counseling in the WHO European Region as an essential component of efforts to achieve universal access to HIV prevention, treatment, care and support. Copenhagen: Author.
- World Health Organization. (2015). Consolidated strategic information guidelines for HIV in the health sector, Switzerland: Author.